La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Qiagen a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Qiagen..

Qiagen (NYSE:QGEN) Azioni, Catena delle Opzioni

Qiagen

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Qiagen NV

Qiagen N.V.

<ul>
<li>QIAcuity digital PCR kits, assays and protocols for lentivirus-based therapies support quality control in cell and gene therapy manufacturing</li>
<li>Expansion underscores the commitment of QIAGEN to help accelerate the development of safe and effective biotherapeutics</li>
<li>New solutions support high-precision analytics for process development, batch release and regulatory compliance and enable a standardized workflow</li>
</ul>
QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow that now includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T), a personalized form of cancer immunotherapy.
This expanded offering supports standardized, high-precision quality control (QC) workflows and strengthens the position of QIAGEN as a trusted partner for quality control, supporting biotech and biopharma companies, Contract Development and Manufacturing Organizations (CDMO) and therapy developers in CGT manufacturing.
"Cell and gene therapy developers face increasing demands for precise, scalable solutions to help ensure therapy safety and efficacy," said Justus Krause-Harder, Vice President and Head of Molecular Tools &amp; Oncology at QIAGEN. "With our expanded dPCR portfolio, we are not only meeting the needs of lentivirus-based therapies but also reaffirming our long-term commitment as a partner for quality control in CGT development and manufacturing."
The additions to QIAGEN's offering of dPCR solutions for lentiviral vectors and their characterization include:
<ul>
<li>The QIAcuity RCL Quant Kit detects replication-competent lentivirus (RCL), a key safety concern in lentiviral vector production. The kit uses clear step-by-step protocols to find even small amounts of RCL, helping therapy developers meet regulations and keep treatments safe.</li>
<li>The new QIAcuity CGT dPCR assays, including eight different wet-lab verified lentiviral targets, are designed for viral vector genome titration (measuring the amount of therapeutic virus particles) and vector copy number (VCN) determination (counting how many copies of a gene are inserted into each cell). The assays offer superior accuracy, reproducibility and speed on the QIAcuity Digital PCR System and enable singleplex and multiplex applications for a streamlined, high-throughput workflow. Together with QIAcuity nanoplates and dedicated master mixes, these assays deliver absolute quantification of viral titer (the concentration of virus particles in a sample) and vector copy number determination, which are crucial for biopharmaceutical manufacturing and quality control processes.</li>
<li>The new CGT Lentivirus Lysis Kit and protocol, combined with QIAcuity CGT dPCR assays, enables vector genome titer quantification with fewer hands-on steps, enhanced accuracy and repeatability. It supports standardized titer quantification from lentivirus particles, promotes robust QC and improved operating procedures, and is ideal for drug development and manufacturing in CGT.</li>
</ul>
These new solutions join the growing portfolio of cell and gene therapy dPCR assays for the biopharma market, including residual DNA quantification kits for commonly used production cell lines such as Human Embryonic Kidney 293 (HEK293), E. coli, and Chinese Hamster Ovary (CHO) cells, mycoplasma quantification kit, adeno-associated virus (AAV) application, viral titer assays and solutions to determine viral vector integrity.

Biotech

News

General

QGEN

QIAGEN Expands Digital PCR Portfolio With New Lentivirus Solutions To Strengthen Cell And Gene Therapy Quality Control

Baird analyst Catherine Schulte maintains Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Neutral and raises the price target from $42 to $43.

Price Target

Analyst Ratings

Baird Maintains Neutral on Qiagen, Raises Price Target to $43

<a href="https://www.bloomberg.com/news/articles/2025-04-15/fivespan-is-said-to-build-stake-in-life-sciences-group-qiagen" title="https://www.bloomberg.com/news/articles/2025-04-15/fivespan-is-said-to-build-stake-in-life-sciences-group-qiagen">https://www.bloomberg.com/news/articles/2025-04-15/fivespan-is-said-to-build-stake-in-life-sciences-group-qiagen</a>

Rumors

Watching Qiagen N.V.; Hearing Fivespan Is Said To Build Stake In Life Sciences Group Qiagen

<ul>
<li>Three new innovative instrument launches expand reach into further lab segments and sample preparation customers as QIAGEN strengthens market-leading position</li>
<li>QIAsymphony Connect set to start phased launch in 2025, first customer sessions being held to highlight enhanced capabilities for oncology and genomics workflows</li>
<li>QIAsprint and QIAmini on track for 2026 launches, expanding options for high- and low-throughput lab demands</li>
</ul>
 &nbsp;

QIAGEN To Launch Three New Sample Prep Instruments By 2026, Expanding Automation From Low To High Throughput Labs

<ul>
<li>QIAGEN provides clinical decision support through its QIAGEN Clinical Insights Interpret One software for expanded Marsden360 liquid biopsy service now offering ESR1 circulating tumor DNA testing for breast cancer patients</li>
<li>Marsden360 offers a minimally invasive alternative to tissue biopsies, enabling rapid identification of mutations in patients with solid tumors</li>
<li>QIAGEN Clinical Insight Interpret One enables reliable variant interpretation by combining AI and human curation, ultimately leading to actionable insights improving patient outcomes</li>
</ul>
 Redwood City, California -- QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN and the leading provider of bioinformatics software and biomedical knowledge content, today announced that its variant interpretation and reporting software, QIAGEN Clinical Insight (QCI) Interpret One, is supporting The Royal Marsden National Health Service (NHS) Foundation Trust's new offering for ESR1 genomic testing, a mutation associated with breast cancer, as part of its workflow for Marsden360, an innovative liquid biopsy service.
On January 20, 2025, the NHS expanded its National Genomic Test Directory to include ESR1 circulating tumor DNA (ctDNA) testing for breast cancer patients. This milestone enables oncologists to detect ESR1 mutations through a simple blood test, guiding personalized treatment strategies for patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer.
Since its launch in 2021, Marsden360 is available for private and clinical trial patients at the Royal Marsden Hospital, a specialist oncology hospital in London, United Kingdom. The service has completed thousands of ctDNA tests as part of an NHS England national study and is advancing toward inclusion in the insurance-covered test directory.
Marsden360 is a blood-based test that analyzes 74 genes to detect genetic mutations in ctDNA, providing a minimally invasive alternative to traditional biopsies. The service enables oncologists to rapidly identify genetic changes in patients with solid tumors, guiding personalized treatment strategies - especially for cases where tissue biopsies are not feasible.
By integrating QCI Interpret One, clinicians gain unmatched accuracy, speed, and consistency in variant interpretation, allowing them to deliver high-confidence, actionable insights for precision oncology treatments.

QIAGEN's QCI Interpret One Selected By Royal Marsden NHS Foundation Trust To expand Marsden360 Liquid Biopsy Service For ESR1 Testing For Breast Cancer Patients

WIIM

Qiagen shares are trading higher following the company's prelim. Q1 results.

Qiagen N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) shares are trading higher premarket on Monday. On Sunday, the company disclosed its preliminary results for the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44658748/qiagen-delivers-strong-preliminary-q1-2025-results-exceeding-outlook-and-raises-full-year-2025-adj" rel="noreferrer noopener">first quarter of 2025</a>.
The company sees net sales growth of around 5% (+7% at constant exchange rates, CER) to about $483 million vs. consensus of $506.5 million.
The revenue figure surpassed the previously communicated outlook of about 3% CER growth (4% CER core business, excluding discontinued products such as NeuMoDx and Dialunox).
The company expects an adjusted EPS of at least $0.55 (vs. the street view of $0.56) in CER in the quarter, compared to prior guidance of about $0.50 CER.
Qiagen anticipates that the QuantiFERON latent TB test sales will increase by around 15% at CER, driven by the continued global shift from the traditional skin test to this reliable, modern, blood-based alternative.
The QIAstat-Dx syndromic testing system is expected to grow by over 35% CER, fueled by strong demand for respiratory panels and expansion in gastrointestinal and meningitis testing.
Both the QIAcuity digital PCR system and QIAGEN Digital Insights bioinformatics business are projected to show high single-digit CER growth, reflecting strong adoption in research and clinical settings.
However, Sample Technologies sales are expected to decline by 1% CER, reflecting a cautious spending environment among some Life Sciences customers for instruments.
2025 Outlook: The company raised the adjusted EPS outlook to about $2.35 in CER from <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$2.28 prior (vs. consensus of $2.48)</a>.
The outlook reflects strong sales in the first quarter, expected headwinds from the recently announced U.S. import tariffs and a better-than-expected tax environment.
Meanwhile, Qiagen reiterated the outlook for the adjusted operating income margin to be above 30% for the year.
QIAGEN now expects to achieve its mid-term target for an adjusted operating income margin of at least 31% significantly earlier than planned, well ahead of the original 2028 timeline.
This acceleration reflects stronger-than-expected performance improvements realized throughout 2024 and into 2025.
The company plans to release the first <a href="https://www.benzinga.com/earnings">quarter of 2025 results on May 7, 2025</a>.
Investors can gain exposure to the stock via&nbsp;Global X Genomics &amp; Biotechnology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNOM#NASDAQ">GNOM</a>) and First Trust Nasdaq Lux Digital Health Solutions ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKG#NASDAQ">EKG</a>).
Price Action: QGEN shares are up 3.06% at $39.43 premarket at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/04/44658456/sp500-fell-9-1-last-week-and-these-large-cap-stocks-were-obliterated-mar-31-apr-4" target="_blank" rel="noreferrer noopener">S&amp;P500 Fell 9.1% Last Week And These Large Cap Stocks Were Obliterated (Mar 31-Apr 4)</a></li>
</ul>
Photo: Shutterstock

Earnings

Equities

Mid Cap

Guidance

Movers

GNOM

Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance

<ul>
<li>Q1 2025 preliminary net sales rise 7% CER and adjusted diluted EPS results of at least $0.55 CER both above outlook despite challenging macro environment</li>
<li>Full-year 2025 adjusted diluted EPS outlook raised to about $2.35 CER (prior outlook about $2.28 CER)</li>
<li>On track to exceed 31% CER adjusted operating income margin ahead of 2028 mid-term target</li>
</ul>

Reported Sunday, QIAGEN Preliminary Q1 2025 Revenue ~$483M And Expects Adj. EPS Of At least $0.55 (Vs. $0.56 Est.); Raised 2025 EPS Target To ~$2.35 (Vs. $2.48 Est.) From Prior $2.28

Redburn Atlantic analyst Ed Ridley-Day downgrades Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) from Buy to Neutral.

Downgrades

Redburn Atlantic Downgrades Qiagen to Neutral

<ul>
<li>Malaria remains a major global health threat, with more than 250 million cases and 600,000 deaths in 2024 – over 90% of them in Africa</li>
<li>QIAprep&amp;amp Plasmodium Kit enables streamlined detection of five malaria-causing parasites for epidemiological research and surveillance</li>
<li>Novel QIAGEN assays support mixed-infection tracking, vaccine impact assessment and malaria control strategies in regions with limited healthcare infrastructure</li>
</ul>

QIAGEN's QIAprep Plasmodium Kit Supports Global Malaria Efforts With Enhanced Detection Of Mixed Infections And Parasite Strains

Zymo Research said it is pleased with the Court's ruling and expects that its antitrust claims will be further vindicated through discovery and trial.

Legal

Zymo Research Says Court Denied QIAGEN GmbH's Partial Motion To Dismiss And In The Alternative, To Stay Certain Counterclaims Brought By Zymo

QIAGEN Announced That The U.S. Food And Drug Administration (FDA) Has Cleared The QIAstat-Dx Gastrointestinal Panel 2 Mini B For Clinical Use, Further Strengthening Its Syndromic Testing Portfolio In The United States

QIAGEN files lawsuit against bioMérieux with German Unified Patent Court to protect key innovations in its QuantiFERON technologyQuantiFERON-TB Gold Plus plays a critical role in fighting the spread of TB worldwide
<ul>
<li>QIAGEN files lawsuit against bioMérieux with German Unified Patent Court to protect key innovations in its QuantiFERON technology</li>
<li>QuantiFERON-TB Gold Plus plays a critical role in fighting the spread of TB worldwide</li>
</ul>

QIAGEN Files Lawsuit To Protect QuantiFERON Technology Amid Tuberculosis Testing Patent Dispute

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Catherine Schulte downgraded the rating for Qiagen N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) from Outperform to Neutral and lowered the price target from $52 to $42. Qiagen shares closed at $40.01 on Tuesday. <a href="https://www.benzinga.com/quote/QGEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Catherine Schulte downgraded Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) from Outperform to Neutral and lowered the price target from $88 to $68. Bio-Techne shares closed at $65.29 on Tuesday. <a href="https://www.benzinga.com/quote/TECH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Keith Weiss downgraded Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) from Overweight to Equal-Weight and lowered the price target from $330 to $275. Workday shares closed at $265.72 on Tuesday. <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities analyst Kyle Bauser downgraded the rating for Tactile Systems Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) from Buy to Neutral and slashed the price target from $23 to $18. Tactile Systems shares closed at $17.86 on Tuesday. <a href="https://www.benzinga.com/quote/TCMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Kristen Kluska downgraded Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) from Overweight to Neutral and lowered the price target from $57 to $36. Supernus Pharmaceuticals shares closed at $39.75 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying WDAY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="427" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168-1024x427.png" alt="" class="wp-image-788949" style="width:460px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168-1024x427.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168-300x125.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168-768x320.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168.png 1527w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

CRVO

SUPN

TCMD

TECH

WDAY

This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Baird analyst Catherine Schulte downgrades Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) from Outperform to Neutral and lowers the price target from $52 to $42.

Baird Downgrades Qiagen to Neutral, Lowers Price Target to $42

UBS analyst John Sourbeer maintains Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Neutral and lowers the price target from $50 to $48.

UBS Maintains Neutral on Qiagen, Lowers Price Target to $48

Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) reported its Q4 earnings results on Wednesday, February 5, 2025 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Qiagen missed estimated earnings by -2.0%, reporting an EPS of $0.61 versus an estimate of $0.62.
Revenue was up $11.84 million from the same period last year.
<h3>Overview of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.03, leading to a 1.0% increase share price change the next day.
Here's a look at Qiagen's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.54</td>
<td>0.51</td>
<td>0.44</td>
<td>0.53</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.57</td>
<td>0.55</td>
<td>0.46</td>
<td>0.55</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>491.75M</td>
<td>494.49M</td>
<td>457.33M</td>
<td>501.28M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>502.00M</td>
<td>496.00M</td>
<td>458.80M</td>
<td>509.16M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Qiagen <a href="https://www.benzinga.com/quote/QGEN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Qiagen Earnings Review: Q4 Summary

Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) reported its Q4 earnings results on Wednesday, February 5, 2025 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Qiagen missed estimated earnings by -2.0%, reporting an EPS of $0.61 versus an estimate of $0.62.
Revenue was up $11.84 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
Last quarter the company beat on EPS by $0.03 which was followed by a 1.0% increase in the share price the next day.
Here's a look at Qiagen's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.54</td>
<td>0.51</td>
<td>0.44</td>
<td>0.53</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.57</td>
<td>0.55</td>
<td>0.46</td>
<td>0.55</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>491.75M</td>
<td>494.49M</td>
<td>457.33M</td>
<td>501.28M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>502.00M</td>
<td>496.00M</td>
<td>458.80M</td>
<td>509.16M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Qiagen <a href="https://www.benzinga.com/quote/QGEN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Qiagen Q4 Earnings Report: What Investors Need to Know

The Q4 earnings report for Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) was released on Wednesday, February 5, 2025 at 04:05 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Qiagen missed estimated earnings by -2.0%, reporting an EPS of $0.61 versus an estimate of $0.62.
Revenue was up $11.84 million from the same period last year.
<h3>Historical Earnings Summary</h3>
During the previous quarter, the company beat on EPS by $0.03, leading to a 1.0% increase share price change the next day.
Here's a look at Qiagen's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.54</td>
<td>0.51</td>
<td>0.44</td>
<td>0.53</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.57</td>
<td>0.55</td>
<td>0.46</td>
<td>0.55</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>491.75M</td>
<td>494.49M</td>
<td>457.33M</td>
<td>501.28M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>502.00M</td>
<td>496.00M</td>
<td>458.80M</td>
<td>509.16M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Qiagen <a href="https://www.benzinga.com/quote/QGEN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Qiagen Q4 Earnings

Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) announced its Q4 earnings on Wednesday, February 5, 2025 at 04:05 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Qiagen missed estimated earnings by -2.0%, reporting an EPS of $0.61 versus an estimate of $0.62.
Revenue was up $11.84 million from the same period last year.
<h3>Overview of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.03, leading to a 1.0% increase share price change the next day.
Here's a look at Qiagen's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.54</td>
<td>0.51</td>
<td>0.44</td>
<td>0.53</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.57</td>
<td>0.55</td>
<td>0.46</td>
<td>0.55</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>491.75M</td>
<td>494.49M</td>
<td>457.33M</td>
<td>501.28M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>502.00M</td>
<td>496.00M</td>
<td>458.80M</td>
<td>509.16M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Qiagen <a href="https://www.benzinga.com/quote/QGEN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Qiagen

Qiagen (QGEN) Opzioni

Qiagen (NYSE:QGEN) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO